UNSPSC 51373408: Ammonium/antimony/chlorpheniramine/codeine/potassium guaiacolsulfonate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373408 Ammonium/antimony/chlorpheniramine/codeine/potassium guaiacolsulfonate is a Commodity code that does not align with recent state and local procurement activity posted under it. The two solicitations on record — one from Seminole County, Florida for naloxone and drug deactivation systems, and one from the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) for generic multi-source pharmaceuticals and over-the-counter products — involve pharmaceutical procurement but do not correspond to the specific chemical compound identified in the code's nominal scope. The Seminole County opportunity is a straightforward purchase of finished naloxone products and equipment for community health initiatives, while the MMCAP RFP targets manufacturers willing to supply multiple generic pharmaceuticals through authorized wholesale distributors across state and local government facilities. Neither opportunity explicitly requires the ammonium/antimony/chlorpheniramine/codeine/potassium guaiacolsulfonate formulation named in the code.

The issuing bodies are a Florida county and a multi-state cooperative purchasing alliance administered by Minnesota's Department of Administration, representing different procurement vehicles and geographic reach. The Seminole County IFB (posted June 30, 2026, response due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida; the MMCAP RFP (posted January 20, 2026, response due March 26, 2026) establishes framework contracts for generic pharmaceuticals across participating state and local government facilities in Minnesota and Oregon. Activity under this code appears limited and mismatch-prone; firms should verify whether opportunities tagged to this code genuinely require the specific formulation or whether the code has been incorrectly applied to broader pharmaceutical procurement.